Recentin
Recentin disappoints in colorectal cancer
March 9, 2010Research and Development AZ, Cancer, Recentin, colorectal cancer
AstraZeneca’s developmental oncology drug Recentin has failed to meet its primary endpoint in a phase II/III study. The once-daily oral …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
